Across TCGA pan-cancer cohorts, TINAGL1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TINAGL1 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher TINAGL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TINAGL1 expression acts as an unfavorable survival marker.
READ, LUAD, and LUSC are the cancer types where TINAGL1 Mutation most reproducibly stratifies survival.